Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: (1) a Circulation mechanistic study reveals that ponatinib triggers TNFR2-mediated endothelial and thromboinflammatory activation leading to plaque inflammation, myocardial infarction, and stroke in mice—effects not seen with asciminib—and preventable by TNF receptor blockade; (2) single-cell multi-omics of acute/fulminant myocarditis identifies a specialized, clonally expanded cytotoxic/migratory CD8 T-cell subset with translational targets va
Summary
Three impactful cardiology studies stood out today: (1) a Circulation mechanistic study reveals that ponatinib triggers TNFR2-mediated endothelial and thromboinflammatory activation leading to plaque inflammation, myocardial infarction, and stroke in mice—effects not seen with asciminib—and preventable by TNF receptor blockade; (2) single-cell multi-omics of acute/fulminant myocarditis identifies a specialized, clonally expanded cytotoxic/migratory CD8 T-cell subset with translational targets validated in a viral myocarditis model; (3) a network meta-analysis of 28 RCTs in ACS shows IVUS- and FFR-guided PCI reduce MACE versus angiography, with QFR reducing all-cause mortality.
Research Themes
- Cardio-oncology mechanistic toxicity and safer kinase inhibition
- Immune pathogenesis and therapeutic targeting in fulminant myocarditis
- Optimization of ACS PCI using intravascular imaging and physiology
Selected Articles
1. Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.
Ponatinib uniquely activates endothelial TNFR2 signaling, leukocytes, and platelets, driving thromboinflammation, plaque destabilization, and death from MI and stroke in mice, whereas asciminib lacks these effects. Pharmacologic TNF/TNFR pathway inhibition prevented ponatinib-induced vascular activation and events, nominating both a safer Abl inhibitor (asciminib) and TNFR2 signaling as actionable cardio-oncology targets.
Impact: This study clarifies the mechanistic basis of ponatinib’s arterial events and demonstrates a protective strategy, directly informing safer kinase inhibitor choices and potential cardioprotective co-therapies.
Clinical Implications: Prefer asciminib over ponatinib when oncologically appropriate; consider vigilant cardiovascular risk assessment in ponatinib-treated patients. TNF/TNFR pathway modulation may emerge as a cardioprotective strategy pending clinical validation.
Key Findings
- Ponatinib, but not asciminib or imatinib, increased endothelial TNFR expression, adhesion molecules (P-selectin, ICAM1, VCAM1), and activated TNFR2 signaling.
- In murine models, ponatinib increased leukocyte rolling/adhesion, platelet-leukocyte aggregates, plaque necrotic core and inflammation, accelerating death from MI and stroke.
- Pharmacologic TNFR inhibition or TNFR2 knockdown blocked endothelial activation, reduced plaque inflammation, and prevented MI/stroke in vivo.
Methodological Strengths
- Convergent evidence across multiple in vivo models (SR-BI-mut/LDLR-KO, ApoE-KO, C57BL/6J) and human endothelial cells
- Mechanistic validation using TNFR pharmacologic inhibition and TNFR2 siRNA knockdown
Limitations
- Preclinical models may not fully recapitulate human cardio-oncology toxicity landscapes
- No randomized clinical data on TNFR blockade as cardioprotection in ponatinib-treated patients
Future Directions: Prospective clinical studies comparing asciminib vs ponatinib cardiovascular outcomes; early-phase trials testing selective TNFR2 or TNF pathway modulation as cardioprotection in high-risk patients.
BACKGROUND: Imatinib, the first Abl-tyrosine kinase inhibitor (TKI), improved leukemia outcomes without cardiovascular side effects. Newer agents, including ponatinib, addressed imatinib resistance, improving cancer remission, but substantially increased arterial thrombotic events, including myocardial infarction (MI) and stroke. The mechanism behind ponatinib-induced thrombosis and the cardiovascular effect of asciminib, a newly approved Abl-TKI, remain unknown. METHODS: The effect of clinically relevant plasma concentrations of imatinib, ponatinib, and asciminib were compared with vehicle in vivo using SR-BI-mut/LDLR-knockout (KO) mice to assess spontaneous MI and stroke risk. The mechanism was interrogated in C57BL/6J mice, assessing leukocyte trafficking and thromboinflammation by intravital microscopy and flow cytometry, respectively, and in ApoE-KO mice, assessing plaque phenotype by flow cytometry and histology. In vitro effects on human umbilical vein endothelial cells (ECs) and human coronary artery ECs were determined by flow cytometry, PCR, and immunoblotting. The role of TNF (tumor necrosis factor) signaling was evaluated by pharmacological inhibition and small interfering RNA knockdown. RESULTS: In SR-BI-mut/LDLR-KO mice, ponatinib significantly accelerated death from MI and stroke compared with vehicle, imatinib, and asciminib. In human ECs, only ponatinib increased expression of TNF receptors (TNFRs) and adhesion molecules (P-selectin, ICAM1 [intercellular adhesion molecule 1], and VCAM1 [vascular cell adhesion molecule 1]). Ponatinib rapidly induced TNFR2 membrane trafficking and TNF signaling in human umbilical vein ECs. TNFR inhibition or TNFR2 knockdown prevented ponatinib induction of EC adhesion molecules. In vivo, ponatinib increased mesenteric vessel adhesion molecules, leukocyte rolling and adhesion to vessels, leukocyte and platelet activation, and platelet-leukocyte aggregates. In ApoE-KO mice, ponatinib increased plaque necrotic core and inflammation, consistent with a rupture-prone phenotype. Asciminib-treated mice developed none of these in vitro or in vivo toxicities. In C57BL/6J mice, TNFR inhibition blocked ponatinib-induced mesenteric adhesion molecule expression and leukocyte trafficking, but not platelet-leukocyte aggregation. TNFR blockade prevented ponatinib-induced plaque inflammation in ApoE-KO mice and MI and stroke in SR-BI-mut/LDLR-KO mice. CONCLUSIONS: Ponatinib, a potent anticancer therapy, activates ECs, platelets, and leukocytes, driving plaque inflammation and death from MI and stroke in mice, mirroring clinical cardiotoxicities in patients with cancer. Asciminib did not induce these effects, suggesting it might be a safer option for imatinib-resistant patients with cancer. Inhibition of TNFR-mediated endothelial activation is sufficient to prevent ponatinib-induced major adverse cardiovascular events.
2. Single-Cell Multi-Omics Identifies Specialized Cytotoxic and Migratory CD8
Using integrated single-cell multi-omics in 40 AM/FM patients, the authors identified a specialized cytotoxic/migratory CD8 T-cell subset, with clonal expansion highlighted (CD57+ signature), implicated in FM pathogenesis. Functional validation and pharmacological blockade in a coxsackievirus B3 FM mouse model support these cells as therapeutic targets.
Impact: This study provides a high-resolution immune map of fulminant myocarditis and nominates a clonally expanded CD8 T-cell subset as a tractable target, bridging discovery to preclinical therapeutic testing.
Clinical Implications: If validated, targeted modulation of pathogenic CD8 T-cell programs could enable precision immunotherapy in fulminant myocarditis; circulating immune signatures may aid risk stratification.
Key Findings
- Integrated scRNA-seq, scTCR-seq, CyTOF, and proteomics in 40 AM/FM patients identified a specialized cytotoxic/migratory CD8 T-cell subset with clonal expansion signature (CD57 highlighted).
- Functional assays and inducing-signal studies supported pathogenicity of the identified CD8 subset.
- In a coxsackievirus B3-induced fulminant myocarditis mouse model, analogous immune changes were observed and pharmacologic blockade of key molecules showed therapeutic potential.
Methodological Strengths
- Multi-omics integration (scRNA/scTCR-seq, CyTOF, proteomics) in human cohort with in vitro validation
- In vivo corroboration and interventional testing in a relevant viral myocarditis model
Limitations
- Sample size is modest (n=40) and clinical endpoints were not primary outcomes
- Abstracted details of the CD8 subset phenotype and specific targets are truncated; full mechanisms require review of the complete article
Future Directions: Prospective validation of circulating pathogenic CD8 signatures, target prioritization, and early-phase trials testing selective blockade in FM; biomarker-driven stratification strategies.
BACKGROUND: Acute myocarditis (AM), particularly fulminant myocarditis (FM), is an infrequent but life-threatening cardiac inflammation, with limited effective precision-targeted treatments available. This urgent clinical challenge has prompted further investigations into the mechanisms underlying this pathology to develop novel therapeutic approaches. METHODS: We enrolled 40 patients diagnosed with AM (24 mild, 16 fulminant) between December 2022 and November 2023. Using a multi-omics approach, we analyzed peripheral blood mononuclear cells and plasma, integrating single-cell RNA sequencing, single-cell T-cell receptor sequencing, cytometry by time of flight, and Olink proteomics to identify specific pathogenic immune subsets and molecular alterations. In vitro experiments validated the function and inducing signals of identified pathogenic subsets. In coxsackievirus B3-induced FM mice, cytometry by time of flight analysis was performed on peripheral blood mononuclear cells and cardiac infiltrating immune cells. Pharmacological blockade of key molecules was tested to assess potential therapeutic efficacy. RESULTS: We identified that a specialized type of CD8 CONCLUSIONS: Our study provides a comprehensive immune landscape for understanding the pathogenesis of AM, especially in FM, highlighting clonal CD57
3. Comparison of intravascular imaging, physiological assessment and angiography for coronary revascularization in acute coronary syndrome: a systematic review and network meta-analysis.
Across 28 RCTs (n=18,221), IVUS- and FFR-guided PCI reduced MACE versus angiography alone, and QFR-guided PCI lowered all-cause mortality. Subgroup analyses showed some inconsistency for IVUS when segregating optimization vs decision-making roles, but overall ranking favored IVUS in ACS PCI.
Impact: This synthesis supports routine use of intravascular imaging and physiology to improve outcomes in ACS PCI and may influence procedural standards and training.
Clinical Implications: Where available, use IVUS or FFR to guide ACS PCI to reduce MACE; QFR offers a nonhyperemic alternative that may confer mortality benefit, warranting broader evaluation and implementation.
Key Findings
- IVUS-guided PCI reduced MACE versus angiography alone (RR 0.62; 95% CI 0.46–0.85).
- FFR-guided PCI reduced MACE versus angiography alone (RR 0.62; 95% CI 0.46–0.85) and lowered all-cause mortality versus angiography (RR 0.64; 95% CI 0.44–0.91).
- QFR-guided PCI lowered all-cause mortality versus angiography (RR 0.25; 95% CI 0.07–0.92); overall ranking favored IVUS in ACS.
Methodological Strengths
- Network meta-analysis of 28 randomized trials with 18,221 patients and registered protocol
- Sensitivity analyses and subgroup assessments for strategy roles (decision-making vs optimization)
Limitations
- Heterogeneity in trial designs and endpoints; subgroup inconsistency for IVUS roles
- Potential publication bias and assumptions inherent to network meta-analysis
Future Directions: Pragmatic RCTs comparing imaging/physiology strategies head-to-head in ACS, cost-effectiveness analyses, and implementation studies to expand access to IVUS/FFR/QFR.
BACKGROUND: The optimal percutaneous coronary intervention (PCI) technique to treat acute coronary syndrome (ACS) requires further investigation. This network meta-analysis evaluated the effects of physiological assessment and intravascular imaging techniques on the prevalence of adverse cardiac outcomes following PCIs. METHODS: We reviewed PubMed, Cochrane, and EMBASE databases for the purpose of identifying all randomized control trials published up to October 30, 2024, comparing the impact of intravascular imaging, physiology assessment, or angiography techniques on outcomes. The primary outcome for this research was major adverse cardiovascular events (MACE) occurrences. Each PCI strategy was ranked RESULTS: Twenty-eight RCTs with 18,221 patients were identified. Compared with angiography, intravascular ultrasound (IVUS)- (RR: 0.62; 95%CI: 0.46-0.85) and fractional flow reserve (FFR)-guided PCI (RR: 0.62; 95%CI: 0.46-0.85) reduced the risk of MACE. Patients who received quantitative flow ratio (QFR)-guided PCI experienced lower all-cause mortality (RR: 0.25; 95%CI: 0.07-0.92) vs. those receiving angiography. Similarly, the RR decreased to 0.64 after using FFR-guided PCI vs. angiographic procedures (95% CI: 0.44-0.91). Compared to angiography, the subgroup analysis showed inconsistent results for IVUS-guided PCI in preventing MACE for both the optimization (RR: 0.60; 95%CI: 0.49-0.74) and decision-making (RR: 0.55; 95%CI: 0.05-6.18). The likelihood of developing MACE was lower for FFR-guided CR than for angiography-guide culprit-only PCIs (RR-0.72; 95%CI: 0.53-0.97), as confirmed by sensitivity assessment results. The research unveiled no statistically significant differences between FFR-guided culprit-only PCIs and culprit-only PCIs or angiography-guided CR. CONCLUSION: IVUS- and FFR-guided PCI lowers the MACE risk in patients with ACS. In addition, IVUS achieved the best results in ACS patients undergoing PCI. SYSTEMATIC REVIEW REGISTRATION: INPLASY (inplasy.com), INPLASY202420092.